Modular Medical, Inc. reports developments tied to its diabetes-focused medical device business and its Pivot tubeless insulin patch pump. The company is a development-stage insulin delivery technology company using patented technologies to support insulin pump adoption among people with diabetes. Pivot is described as a two-part tubeless patch pump with a removable 3 mL reservoir, disposable battery, and smartphone connectivity for bolus and monitoring.
Recurring MODD news includes FDA 510(k) clearance for Pivot, manufacturing validation, commercial-readiness updates, investor presentations, Nasdaq listing compliance, reverse stock split actions, shareholder voting matters, capital-structure disclosures, governance updates, and operating and financial results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Modular Medical, Inc. (NASDAQ:MODD) has updated its progress on the MODD-1 insulin pump, transitioning to a full commercial version designed with a tier-1 medical product manufacturer. This new version aims to resolve prior material compatibility issues, enhance cost-effectiveness, and streamline usability. The company anticipates submitting the device for FDA approval in the quarter ending December 31, 2023, following the arrival of key production equipment and subsequent testing. The initiative seeks to make insulin delivery technology more accessible and user-friendly for diabetes patients.
Modular Medical (NASDAQ:MODD) has updated on the development of its insulin pump product, MODD1. The company is making progress on the testing needed for its 510(k) submission to the FDA. However, they encountered compatibility issues with certain materials used in the device, delaying the submission timeline. Replacement materials have been identified and are in the qualification process. Modular Medical now anticipates submitting to the FDA by June 30, 2023, pending resolution of these issues.
Modular Medical, Inc. (NASDAQ:MODD) announced plans for Chief Executive Officer Jeb Besser to present at upcoming investor conferences. Besser will speak at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 10:50 a.m. ET, and will also conduct one-on-one meetings. The following day, he will host one-on-one meetings at the Benchmark Company's 11th Annual Discovery Investor Conference. Modular Medical aims to revolutionize insulin delivery technology, making it simpler and more affordable for diabetes patients.
Modular Medical Inc. (NASDAQ:MODD) has updated investors on its insulin pump product, the MODD1. The company is nearing completion of its 510(k) submission to the FDA but has encountered a materials compatibility issue that has delayed the submission timeline, now expected between December 2022 and June 2023. Meanwhile, progress in establishing production capabilities is ahead of schedule and cost estimates are favorable. The CEO will attend investor conferences in late November 2022, with further updates on product development anticipated.